An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack

PHASE3CompletedINTERVENTIONAL
Enrollment

650

Participants

Timeline

Start Date

May 31, 2006

Study Completion Date

December 31, 2006

Conditions
MigrainePhotophobiaPhonophobia
Interventions
DRUG

PRO-513

Trial Locations (16)

10021

New York Headache Center, New York

21286

International Research Center, Towson

22304

The Innovative Clinical Research Center, Alexandria

27401

Headache Wellness Center, Greensboro

33410

Palm Beach Neurological Center, Palm Beach Gardens

33907

LCFP Inc., Fort Myers

48104

Michigan Head-Pain and Neurologic Institute, Ann Arbor

53209

Advanced Healthcare, S.C., Milwaukee

60614

Diamond Headache Clinic, Chicago

63141

Mercy Health Research, St Louis

77004

Houston Headache Clinic, Houston

77802

J&S Studies, Inc., Bryan

78258

Road Runner Research, Ltd., San Antonio

78759

DermResearch, Inc., Austin

06824

Associated Neurologists of Southern CT, Fairfield

06902

New England Center for Headache, Stamford

Sponsors
All Listed Sponsors
lead

ProEthic Pharmaceuticals

INDUSTRY